Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis

Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis

Objective:Patients with type 2 diabetes have an increased tendency to develop hepatosteatosis. The effects of drugs used to treat diabetes on the liver, regardless of the disease, are unknown.The aim of this study was to investigate the effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on...

Full description

Bibliographic Details
Main Authors:	Cumali KARATOPRAK, Rukiye KILIÇARSLAN, Mustafa ÇAKIRCA, Sinem AYDIN, Tuba ÖZKAN, Mehmet ZORLU, Muharrem KISKAÇ
Format:	Article
Language:	English
Published:	Galenos Publishing House 2019-10-01
Series:	Bezmiâlem Science
Subjects:	di-peptidyl peptidase 4 inhibitors vildagliptin portal vein pressure hepatosteatosis tip 2 diabetes mellitus
Online Access:	http://bezmialemscience.org/archives/archive-detail/article-preview/effects-of-18-month-vildagliptin-treatment-on-port/30625

Similar Items

Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
by: Cumali KARATOPRAK, et al.
Published: (2018-01-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Evaluation of Risk Factors for Hepatosteatosis in Gall Stone Disease
by: Osman Anıl Savaş, et al.
Published: (2015-09-01)

Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity
by: Abdul Samad, et al.
Published: (2024-08-01)

Can portal vein pulsatility index be used as predictive parameter with hepatic artery resistive index for liver fibrosis in nonalcoholic hepatosteatosis?
by: Okan Di̇lek, et al.
Published: (2020-07-01)

The relationship between vitamin D level and hepatosteatosis in obese children
by: Fatma Dursun, et al.
Published: (2019-03-01)

Cardiometabolic risk factors in Turkish children with hepatosteatosis
by: Ahmet Aslan, et al.
Published: (2019-10-01)

Are Mean Platelet Volume and Neutrophil-to-Lymphocyte Ratio Related with Hepatosteatosis in Obese Children?
by: Serdar Kertmen, et al.
Published: (2018-12-01)

Combined saline and vildagliptin induced M2 macrophage polarization in hepatic injury induced by acute kidney injury
by: Shaimaa N. Amin, et al.
Published: (2023-02-01)

Is vitamin D an important factor in hepatosteatosis in childhood obesity?
by: Elif Ozsu, et al.
Published: (2019-12-01)

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
by: Serhat Sayin, et al.
Published: (2018-03-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)

Associations of Adipocyte-derived Versican and Macrophage-derived Biglycan with Body Adipose Tissue and Hepatosteatosis in Obese Children
by: Reyhan Deveci Sevim, et al.
Published: (2024-06-01)

Effect of vildagliptin on atherosclerosis progression in high cholesterol –fed male rabbits
by: Sahar A Majeed
Published: (2014-12-01)

MEAN PLATELET VOLUME AND RED CELL DISTRIBUTION WIDTH IN HEPATOSTEATOSIS
by: Gulali Aktas, et al.
Published: (2013-09-01)

Effects of asparaginases and L-carnitine on Western-diet-induced hepatosteatosis in mice [version 1; peer review: 1 approved, 2 approved with reservations]
by: Julia Steitz, et al.
Published: (2022-02-01)

Cost Utility Analysis Vildagliptin dan Glimepiride dalam Mencegah Komplikasi Mikrovaskuler menggunakan Model Markov
by: Tri Julia Purnamasari, et al.
Published: (2023-12-01)

UJI EFEKTIVITAS DAN KEAMANAN KOMBINASI METFORMIN-VILDAGLIPTIN PADA DIABETES MELITUS TIPE 2 DI RSPAL Dr. RAMELAN SURABAYA
by: Dwi Octamy Sari, et al.
Published: (2023-10-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations
by: Pankaj M. Kharabe, et al.
Published: (2024-08-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing
by: Chen-Hung Lee, et al.
Published: (2023-04-01)

Unraveling the metabolic activities of bioactive compounds on cellular models of hepatosteatosis and adipogenesis through docking analysis with PPARs
by: Farah Diab, et al.
Published: (2024-11-01)

Techniques for portal vein targeting during a transjugular intrahepatic portosystemic shunt
by: Dan Laney, et al.
Published: (2024-01-01)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2013-06-01)

Vildagliptin promotes diabetic foot ulcer healing through autophagy modulation
by: Erik Biros, et al.
Published: (2024-08-01)

Nanofibrous Vildagliptin/PLGA Membranes Accelerate Diabetic Wound Healing by Angiogenesis
by: Chen-Hung Lee, et al.
Published: (2022-11-01)

Association between high on-treatment platelet reactivity to clopidogrel and hepatosteatosis in patients undergoing elective stent implantation
by: Yalçın Velibey, et al.
Published: (2018-07-01)

Portal vein thrombosis after double installation of transjugular intrahepatic portosystemic stent (clinical observation)
by: M. S. Guska, et al.
Published: (2024-04-01)

Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation
by: Mahesh Attimarad, et al.
Published: (2021-10-01)

CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING
by: A. P. TARASOVА, et al.
Published: (2017-09-01)

Safety and feasibility of a novel bi-directional portal vein access kit during transjugular intrahepatic portosystemic shunt creation
by: Richard D. Kang, et al.
Published: (2023-04-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

A new gas chromatographic method for quantification of Metformin hydrochloride and Vildagliptin in bulk and pharmaceutical dosage form: development and validation
by: Popat Mohite, et al.
Published: (2024-04-01)

Vildagliptin: the known and unknown
by: L. Y. Morgunov
Published: (2016-12-01)

Hepatic Artery and Portal Vein Hemodynamics in Nonalcoholic Fatty Liver Disease in Adult Saudi Patients: A Doppler Ultrasound Study
by: Abdullah Sulaiman Alshehri, et al.
Published: (2023-06-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)

TRANSJUGULAR INTRA HEPATIC PORTOSISTEMNY SHUNTING: METHOD OF CORRECTION OF INTRA HEPATIC PORTAL HYPERTENSIA
by: N. G. Sарrоnоvа, et al.
Published: (2014-06-01)

PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN
by: V. K. Bayrasheva, et al.
Published: (2017-12-01)